All News

lectures

Great Lectures; Great Presentations

Jack Cush, MD

Dr. Jack Cush lectures on giving a great presentation; based on 40 years of lecturing in Rheumatology.

Read Article
Tavneos

FDA Targeting the Safety of Avacopan

Jack Cush, MD

The future of avacopan is up in the air. In April, the FDA issued a drug safety warning, previously requesting that Amgen to pull its rare disease drug Tavneos from the market. Now, there appears more pressure to remove it from the market.

Read Article
exercise,group

EULAR Recommendations for Physical Activity in Arthritis

Jack Cush, MD

EULAR has published a 2025 update for physical activity recommendations for patients with osteoarthritis (OA) and rheumatoid arthritis (RA). 

Read Article
38420215_s.jpg

Neoplasia and Autoimmune Disease

Jack Cush, MD

Malignancy rivals cardiovascular disease as a leading cause of death in patients with systemic autoimmune diseases. Chronic inflammation and immune dysregulation can drive oncogenesis, while antitumor immune responses can trigger autoimmune phenomena (paraneoplastic syndromes, checkpoint inhibitor-induced rheumatic disease).

Read Article
choices2.jpg

Switch or Cycle - Upadacitinib vs Adalimumab in Refractory RA

Jack Cush, MD

After the first tumour necrosis factor inhibitor (TNFi) failure, patients with active rheumatoid arthritis (RA) responded by switching to upadacitinib, compared to cycling to a second TNFi, adalimumab.

Read Article
RheumNow Podcast square

Follow the Money (4.23.2026)

Jack Cush, MD

Dr. Jack Cush follows the money and all the news that fits the Rheumatology Gab for this past week. 

Read Article
Knee pain: JAMA review - 5% PCP visits knee pain - Knee OA ~654 million worldwide - Patellofemoral pain: <40 yrs & physically active; pain on squat - Meniscal tears in 12% adults (McMurray 61% sensitive; 84% specific; Joint line tender 83% sensitive; 83% specific) https://t.co/2fdpl464mb
Dr. John Cush RheumNow ( View Tweet)
Prospective study of 305 Consecutive newly diagnosed axSpA pts (55% male; Dx delay 6 yrs; 75% B27+). 56% w/ r-axSpA more male w/ hi CRP. nr-axSpA had more inflam LBP, +FHx SpA. SpA Dx made without sacroiliitis in 12%; only 2/38 later developed sacroiliitis https://t.co/xPlGwZ7Kjk https://t.co/2TBQALvxsG

Links:

Dr. John Cush RheumNow ( View Tweet)
Which autoimmune condition carries the highest relative risk for lymphoma? Test your knowledge in the latest RheumIQ quiz at https://t.co/TBlB4pmnKa https://t.co/sx8fpdHgHN

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR Recommendations for Physical Activity in Arthritis EULAR has published a 2025 update for physical activity recommendations for patients with osteoarthritis (OA) and rheumatoid arthritis (RA). https://t.co/RFECflCUgf https://t.co/Da7D6KpN6q

Links:

Dr. John Cush RheumNow ( View Tweet)
A man spends 50 years teaching at MIT. He knows his time is running out. So he records one last lecture — everything he knows, distilled into a single hour. He died 5 months later. This is that lecture. The most important hour you'll watch this week. 👇 Bookmark it for later https://t.co/tRUH05ysSt

Links:

Suryansh Tiwari Suryanshti777 ( View Tweet)
Sun Pharma buys out Organon w/ $11.75 billion buyout. Both generated $6.2 billion in 2025 sales. Organon spun off from ‌Merck in 2021, specializes in women’s health and is top 7 in biosimilars. Sun is into dermatology, ophthalmology and oncology-dermatology. https://t.co/zb4hucTqCJ
Dr. John Cush RheumNow ( View Tweet)
Presented at AACE Annual Meeting, FREEDOM Real-World Study looked atypical femoral Fxs & found a low AFF risk - 24 AFFs w/ denosumab (0.89/1KPY) vs 397 AFFs w/ bisphosphonates (0.82/1KPY) but no active comparators & excluded pts w/ comorbidities. https://t.co/vRwkfHSXxh https://t.co/xzgC0D5ZTu

Links:

Dr. John Cush RheumNow ( View Tweet)
Obesity is more than comorbidity—it’s a driver of inflammation. At #RheumNowLive 2026, Dr. Uzma Haque breaks down weight management strategies that actually move the needle in rheumatology care. 🎧 Listen here: https://t.co/A6fbPvV2tD #Rheumatology #Inflammation #Obesity https://t.co/RLxV44SrUB

Links:

Dr. John Cush RheumNow ( View Tweet)
“Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill

Dr. John Cush RheumNow ( View Tweet)

Rheumatology Salaries 2025 Medscape has published its annual Physician Compensation report with physican salaries up roughly 3% and eight specialties earning more than $500,000 per annum. https://t.co/DNe42EsxRW https://t.co/aegcNm8Pla

Links:

Dr. John Cush RheumNow ( View Tweet)
Severe thrombocytopenia (TP) assoc w/ severe APS & increased mortality. Retro study of 432 #APS pts - 142 w/ TP (33%): 13% severe TP (<50L G/L). Severe TP assoc w/ ITP & CAP -had higher mortality https://t.co/7f8VpIcEJy

Links:

Dr. John Cush RheumNow ( View Tweet)

Weight-loss drugs may affect joints directly A new study from Aarhus University shows that the hormone GLP-1, which is mimicked in medication for diabetes and weight loss, is present in joint fluid. In the long term, this may open up new treatments for arthritis. https://t.co/HkcPUQp05H
Dr. John Cush RheumNow ( View Tweet)
NSAIDs in Inflammatory Bowel Disease? At least some patients with inflammatory bowel disease (IBD) can safely use common drugs for musculoskeletal aches and pains, a large study of insurance claims data suggested, contradicting a widespread concern that these products can https://t.co/JeINgTWTK0
Dr. John Cush RheumNow ( View Tweet)
GI involvement occurs in 37-65% of adult IgA (IgAV) cases, w/ Sxs of abdominal pain, hematochezia, severe complications of perforation & ischemia. Dx w/ CRP, NLR, D-dimer, imaging (CT, endoscopy). Steroids w/ Mod-to-severe Dz. MMF or IVIG for refractory cases. https://t.co/vgvZnYXIOI
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×